Bleakley Financial Group LLC Sells 2,871 Shares of AbbVie Inc. $ABBV

Posted by Brenda Bartman on Jul 14th, 2026

Bleakley Financial Group LLC lowered its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 3.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 72,543 shares of the company’s stock after selling 2,871 shares during the quarter. Bleakley Financial Group LLC’s holdings in AbbVie were worth $15,777,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in ABBV. Bank of Jackson Hole Trust lifted its position in AbbVie by 0.6% during the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock worth $1,648,000 after buying an additional 44 shares in the last quarter. Eclectic Associates Inc. ADV increased its position in AbbVie by 0.8% in the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after acquiring an additional 45 shares in the last quarter. Imprint Wealth LLC raised its stake in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares during the last quarter. Hardin Capital Partners LLC raised its stake in shares of AbbVie by 1.4% in the fourth quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock worth $759,000 after acquiring an additional 46 shares during the last quarter. Finally, Dogwood Wealth Management LLC lifted its position in shares of AbbVie by 10.8% during the fourth quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after purchasing an additional 46 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $248.06 on Tuesday. The stock has a market cap of $438.27 billion, a price-to-earnings ratio of 122.20, a P/E/G ratio of 0.81 and a beta of 0.30. The company has a 50 day moving average of $226.15 and a 200-day moving average of $221.34. AbbVie Inc. has a one year low of $184.63 and a one year high of $261.64.

AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same period in the prior year, the business posted $2.46 earnings per share. AbbVie’s revenue was up 12.4% compared to the same quarter last year. Equities research analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s dividend payout ratio is 340.89%.

Wall Street Analyst Weigh In

Several analysts have recently commented on ABBV shares. Morgan Stanley increased their price target on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Bank of America increased their price objective on AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research report on Friday. Finally, Royal Bank Of Canada lifted their target price on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $266.24.

View Our Latest Stock Report on ABBV

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.